Answers are grounded in this paper and cite their sources.
Intracerebral hemorrhage (ICH) is a severe stroke subtype with high mortality and limited treatment options. This study evaluated the safety and therapeutic potential of human placenta-derived mesenchymal stem cells (PD-MSCs) in acute ICH. PD-MSCs were isolated, characterized, and assessed for tumorigenicity by subcutaneous implantation in nude mice. Acute ICH was induced in rats by collagenase injection, followed by in situ PD-MSC transplantation. Neurological function, brain water content, and hematoma volume were evaluated, and perihematomal biological changes were examined using immunofluorescence staining, ELISA, and transcriptomic sequencing. PD-MSCs displayed typical mesenchymal stem cell characteristics and showed no evidence of tumorigenicity under the present experimental conditions. In ICH rats, PD-MSC transplantation reduced brain edema and hematoma volume and partially improved neurological outcomes compared with untreated controls. PD-MSC treatment also modulated astrocytic responses, as reflected by altered GFAP expression and astrocyte morphology, and decreased the pro-inflammatory cytokines IL-6 and TNF-α. Transcriptomic analysis indicated that PD-MSCs influenced inflammation-related and immune-regulatory pathways in perihematomal tissues. AKR1B1, SNAI2, and ADGRE5 were identified as candidate genes potentially associated with PD-MSC-mediated responses after ICH. These findings provide preliminary evidence that PD-MSCs are non-tumorigenic and may attenuate acute brain injury after ICH, although longer follow-up, expanded behavioral testing, dose optimization, and mechanistic validation are needed to confirm their long-term safety and therapeutic efficacy.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: